News BioArctic AB

Stocks

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 12/06/2026 BST			5-day change	1st Jan Change
302.40 ^SEK	+4.71%		-1.82%	-2.70%

05-29	Three Nasdaq Stockholm companies trade ex-dividend today	FW
05-29	Calendar Friday May 29	FW

All News

Mentions Relevance

05-29	Number of shares and votes in BioArctic AB (publ) as of May 29, 2026	AQ
05-29	Three Nasdaq Stockholm companies trade ex-dividend today	FW
05-28	BioArctic AB Approves Dividend	CI
05-28	BioArctic AB Approves Board Elections, Effective 28 May 2026	CI
05-28	Bioarctic AB declares dividend of SEK 2 per share with 1 June 2026 record date	RE
05-28	Bulletin from the Annual General Meeting in BioArctic AB (publ)	AQ
05-25	BioArctic partner Eisai presents Leqembi sales simulation	RE
05-25	BioArctic : partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day	PU
05-25	Leqembi sales projected to reach 300 billion yen by end of Eisai fiscal year, simulation shows	FW
05-25	BioArctic partner Eisai presents simulation of potential future Leqembi sales at Capital Markets Day	FW
05-25	BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day	AQ
05-22	DNB Carnegie raises Bioarctic price target to SEK 363 (342), reiterates Buy	FW
05-21	Goldman Sachs cuts Bioarctic price target to SEK 339 (355), reiterates Neutral - BN	FW
05-20	BioArctic AB, Q1 2026 Earnings Call, May 20, 2026
05-20	Bioarctic: Strong royalty growth and milestone payment lift Q1 ahead of consensus	FW
05-20	Interim Report for the period January - March 2026	AQ
05-20	BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-15	Bioarctic expected to report operating profit of SEK 66 million - Modular	FW
05-15	BioArctic – Consensus estimates Q1 2026	AQ
05-15	RX Securities reiterates Buy for Bioarctic - raises fair value	FW
05-15	Bioarctic: Leqembi to generate about SEK 880 million in royalty	RE
05-15	Eisai forecasts robust growth for Leqembi – Bioarctic poised for 880 million SEK in royalties	FW
05-15	Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)	AQ
05-13	Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET	AQ
05-08	US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy	MT